Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Safety and Tolerability Study of Repeated Doses of Anti-IgE Immunotherapy in Allergic Patients

NCT00439621 is registered in ClinicalTrials.gov with Resistentia Pharmaceuticals AB as lead sponsor.

NCT NCT00439621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00439621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Safety and Tolerability Study of Repeated Doses of Anti-IgE Immunotherapy in Allergic Patients
Lead sponsor
Resistentia Pharmaceuticals AB
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2007
Completion date
August 31, 2008
Enrollment
42 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

allergy